The clinical efficacy of nivolumab, an antibody that acts as ICI upon binding to the programmed death-1 receptor (PD-1) and blocking its interaction with PD-L1 and PD-L2 on tumor cells, has been demonstrated through two relevant clinical studies of comparison with sorafenib. Here, CD274 is linked to neoplasm.